Moving into the clinic changes the questions a company must answer and the responsibilities it must manage. A readiness discussion should make those dependencies visible before the study is committed.
Start with what the first study must show
Be explicit about the clinical question and what each possible outcome would teach you. Population, dose strategy, assessments and follow-up should each have a reason tied to that question. An early signal is far easier to interpret when the original assumptions were written down.
Map the dependencies beyond clinical
Clinical plans rest on nonclinical, CMC, regulatory, statistical and clinical-pharmacology input. Record which inputs are firm, which are provisional and which could change the concept. The aim is to connect those conclusions to the clinical plan, not to replace those disciplines.
Decide how the sponsor will operate
Who owns medical review, vendor oversight, escalation and program decisions? A vendor contract does not by itself establish how the sponsor will receive and act on critical information. ICH E6(R3) is a reminder that sponsors keep responsibility for what they delegate. Roles, information flows and response times should be understood before a live issue tests them.
Follow the data from collection to decision
Take a hypothetical patient from the protocol through the CRF and into the reviewer’s hands. Can emerging safety, treatment exposure and clinical activity be seen together? Missing definitions and inconsistent timing are far easier to resolve before the study is running.
Think about dose early
For many oncology agents, the first study is where the dose question begins. FDA’s Project Optimus describes the expectation that dose selection weighs efficacy, safety and tolerability. A design that cannot generate that information leaves the question for a later, more expensive study.
Public reference points
Related service: First-in-human readiness.